Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the company’s reporting as a foreign private issuer and its formal company announcements on antibody-medicine operations, financial results, governance and share capital. Recent Form 6-K reports include interim financial information, DARZALEX® royalty-related sales disclosures from Johnson & Johnson, pipeline commentary for EPKINLY®, Rina-S® and petosemtamab, and updates incorporated by reference into Form S-8 registration statements.
The filing record also documents Danish-market disclosure matters, including major shareholder notifications, managerial transactions in shares and linked securities, amendments to the articles of association, and registered share capital reductions. These filings provide the formal record for Genmab’s capital structure, ownership notifications, governance documents and recurring biotechnology business disclosures.
Genmab A/S, a Denmark-based biotechnology company, submitted a Form 6-K as a foreign private issuer to the U.S. Securities and Exchange Commission for November 2025. The filing primarily makes Genmab’s updated Articles of Association available to U.S. investors as an exhibit.
The report states that this Form 6-K is incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the updated governance document becomes part of those employee share incentive-related registrations. The filing is signed on behalf of the company by Executive Vice President & Chief Financial Officer Anthony Pagano.
Genmab A/S filed a Form 6-K as a foreign private issuer for November 2025. The filing attaches a company announcement dated November 18, 2025 describing a capital increase in Genmab resulting from the exercise of employee warrants.
The Form 6-K is expressly incorporated by reference into Genmab’s existing Form S-8 registration statements, making this capital increase disclosure part of those employee equity compensation-related registrations.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, filed Amendment No. 1 to its tender offer to acquire all outstanding common shares of Merus N.V. (MRUS) for $97.00 in cash per share, less any applicable withholding taxes and without interest.
The parties filed HSR premerger notifications on October 28, 2025. As a result, the required 15‑day waiting period will expire at 11:59 p.m., New York City time, on November 12, 2025, unless withdrawn and refiled, shortened by Early Termination, or extended by a Second Request.
The amendment also updates post‑closing governance plans. If Dr. Lundberg resigns as President and CEO of Merus and Merus US, Inc. following the Closing, Genmab plans for the Merus Board to appoint Dr. Jan G.J. van de Winkel as President and CEO. Genmab and the Purchaser have designated Anthony Pagano, Martine J. van Vugt, Ph.D., and Greg Mueller as non‑executive directors and Dr. van de Winkel as executive director, effective upon Closing and, for the non‑executives, subject to adoption of Governance Resolutions at the EGM or a Subsequent EGM.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, filed Amendment No. 1 to its tender offer to acquire all outstanding common shares of Merus N.V. (MRUS) for $97.00 in cash per share, less any applicable withholding taxes and without interest.
The parties filed HSR premerger notifications on October 28, 2025. As a result, the required 15‑day waiting period will expire at 11:59 p.m., New York City time, on November 12, 2025, unless withdrawn and refiled, shortened by Early Termination, or extended by a Second Request.
The amendment also updates post‑closing governance plans. If Dr. Lundberg resigns as President and CEO of Merus and Merus US, Inc. following the Closing, Genmab plans for the Merus Board to appoint Dr. Jan G.J. van de Winkel as President and CEO. Genmab and the Purchaser have designated Anthony Pagano, Martine J. van Vugt, Ph.D., and Greg Mueller as non‑executive directors and Dr. van de Winkel as executive director, effective upon Closing and, for the non‑executives, subject to adoption of Governance Resolutions at the EGM or a Subsequent EGM.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, commenced a cash tender offer to purchase all issued and outstanding common shares of Merus N.V. (MRUS) for $97.00 per share, less any applicable withholding taxes and without interest. The offer is made upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 21, 2025, together with the accompanying Letter of Transmittal.
The filing lists related exhibits, including the Offer to Purchase, Letter of Transmittal, a media release announcing commencement, and a Debt Commitment Letter with Morgan Stanley Senior Funding, Inc. A Transaction Agreement among Genmab, the Purchaser, and Merus is referenced. Shareholders who tender and whose shares are accepted would receive cash consideration of $97.00 per share under the offer terms.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, commenced a cash tender offer to purchase all issued and outstanding common shares of Merus N.V. (MRUS) for $97.00 per share, less any applicable withholding taxes and without interest. The offer is made upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 21, 2025, together with the accompanying Letter of Transmittal.
The filing lists related exhibits, including the Offer to Purchase, Letter of Transmittal, a media release announcing commencement, and a Debt Commitment Letter with Morgan Stanley Senior Funding, Inc. A Transaction Agreement among Genmab, the Purchaser, and Merus is referenced. Shareholders who tender and whose shares are accepted would receive cash consideration of $97.00 per share under the offer terms.
Genmab A/S submitted a Form 6-K as a foreign private issuer for October 2025. The filing makes a company announcement, dated October 14, 2025, available as an exhibit, which covers net sales of DARZALEX (daratumumab) for the third quarter of 2025.
The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the information in this report becomes part of those employee equity compensation-related disclosures.
Genmab A/S has filed a Form 6-K to furnish a company announcement stating that it plans to acquire Merus. The announcement highlights that the deal is intended to expand Genmab’s late-stage drug pipeline and accelerate a shift toward a wholly owned product model, meaning Genmab aims to control more of its future medicines rather than relying mainly on partnerships.
The Form 6-K is also designated to be incorporated by reference into several existing Genmab registration statements on Form S-8, so the information in this report becomes part of those employee share incentive-related filings.